公开(公告)号：EP2829266A4

公开(公告)日：2015-11-11

申请号：EP13763543

申请日：2013-03-20

申请人： INST PHARM & TOXICOLOGY AMMS

发明人： LI SONG ,  GAO CHUNSHENG ,  ZHONG WU ,  WANG YULI ,  YANG MEIYAN ,  SHAN LI ,  ZHOU XINBO ,  ZHENG ZHIBING ,  WANG XIAOKUI

IPC分类号： A61K9/16 ,  A61K9/48 ,  A61K9/50 ,  A61K9/52 ,  A61K31/35 ,  A61K31/357

CPC分类号： A61K31/357 ,  A61K9/4808 ,  A61K9/5047 ,  A61K9/5078 ,  A61K9/5084 ,  A61K9/5089 ,  A61K31/137 ,  A61K2300/00

公开(公告)号：EP2829267A4

公开(公告)日：2015-09-30

申请号：EP13763714

申请日：2013-03-07

申请人： INST PHARM & TOXICOLOGY AMMS

发明人： LI SONG ,  GAO CHUNSHENG ,  ZHONG WU ,  WANG YULI ,  YANG MEIYAN ,  SHAN LI ,  ZHOU XINBO ,  ZHENG ZHIBING ,  WANG XIAOKUI

IPC分类号： A61K9/22 ,  A61K31/7048 ,  A61K47/32 ,  A61K47/38 ,  A61P3/10 ,  A61P9/12 ,  A61P25/00 ,  A61P25/06 ,  A61P25/08 ,  A61P25/18 ,  A61P25/24

CPC分类号： A61K31/357 ,  A61K9/1676 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5078 ,  A61K9/5089 ,  A61K31/7048

摘要： A sustained-release pharmaceutical composition of topiramate, which is free of binding agent. The sustained-release pharmaceutical composition of topiramate is a sustained-release pellet, comprising a blank pellet core, a drug layer, and a sustained-release coating layer.

公开(公告)号：EP2829270A4

公开(公告)日：2015-09-23

申请号：EP13764754

申请日：2013-03-22

申请人： INST PHARM & TOXICOLOGY AMMS

发明人： LI SONG ,  GAO CHUNSHENG ,  ZHONG WU ,  WANG YULI ,  YANG MEIYAN ,  SHAN LI ,  ZHOU XINBO ,  ZHENG ZHIBING ,  WANG XIAOKUI

IPC分类号： A61K31/357 ,  A61K9/16 ,  A61K9/30 ,  A61K9/50 ,  A61K31/137 ,  A61P3/04

CPC分类号： A61K31/357 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5078 ,  A61K9/5084 ,  A61K9/5089 ,  A61K31/137 ,  A61K31/7048 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention provides a joint product comprising synephrine and topiramate, in which the synephrine or salt thereof is administered in form of rapid-release preparation, preferably rapid-release pellet, having daily dose of 2mg to 25mg, preferably 5mg to 20mg; the topiramate is administered in form of sustained-release or controlled-release preparation, preferably sustained-release pellet, having daily dose of 20mg to 100mg, preferably 23mg to 92mg. The composition is used for treatment of obesity or other diseases associated with obesity.

摘要翻译： 本发明提供了包含昔萘福芬和托吡酯的联合产品，其中以每日剂量为2mg至25mg，优选5mg至20mg的快速释放制剂，优选快速释放丸剂的形式施用昔萘福林或其盐; 托吡酯以持续释放或控释制剂的形式施用，优选缓释丸剂，其日剂量为20mg至100mg，优选为23mg至92mg。 该组合物用于治疗与肥胖相关的肥胖或其它疾病。

公开(公告)号：EP2573067A4

公开(公告)日：2014-10-29

申请号：EP11782849

申请日：2011-05-16

申请人： INST PHARM & TOXICOLOGY AMMS

发明人： LI SONG ,  ZHONG WU ,  LIU PING ,  XIAO JUNHAI ,  ZHENG ZHIBING ,  XIE YUNDE ,  ZHAO GUOMING ,  WANG XIAOKUI ,  WANG LILI ,  LI XINGZHOU ,  ZHOU XINBO

IPC分类号： C07C215/62 ,  A61K31/137 ,  A61P31/06 ,  C07C217/72

CPC分类号： C07C217/72 ,  A61K31/137 ,  C07C213/00 ,  C07C215/62

摘要： The present invention relates to aromatic butan-2-ol compounds and preparation methods and uses thereof. Specifically, the present invention relates to the compound of Formula I, or an optical isomer, racemate, diastereomer, pharmaceutically acceptable salt or solvate thereof: wherein each of the substituents have the definitions as given in the specification. The present invention further relates to a pharmaceutical composition containing the compound, and the use of the compound in manufacture of a medicament for the treatment and/or prophylaxis of a disease or disorder caused by tubercle bacillus infection. The compound of Formula I of the present invention has advantages in treatment and/or prophylaxis of a disease or disorder caused by tubercle bacillus infection.